An interventional study of Non-surgical periodontal treatment and Periodontally healthy group in Periodontal Disease, Saliva and Taurine, sponsored by Ordu University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Ordu University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 160 studies in Periodontal Diseases with a site in Turkey — 25 open to participants now, 34 under way, none of them phase 3. Periodontal Diseases · Turkey.
Among the 160 studies in Periodontal Diseases with a site in Turkey, this one is the 50th largest by enrollment of the 69 interventional ones that give a count, is one of 22 that started in 2026, is one of 66 with no phase, reaches primary completion later than 28 of the 33 other live ones, and was the 159th registered.
871 studies on the registry are indexed under Periodontal Diseases; 191 are open to participants now.
Browse Periodontal Diseases studies →25 of the 160 studies in Periodontal Diseases with a site in Turkey are open now. Recruiting first, the newest first:
Biruni University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18+ · Healthy volunteers
Recep Tayyip Erdogan University Training and Research Hospital · Sites in Turkey
Ages 18–65 · Healthy volunteers
Recep Tayyip Erdogan University Training and Research Hospital · Sites in Turkey
Ages 18–70 · Healthy volunteers
Saglik Bilimleri Universitesi · Sites in Turkey
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 102 Periodontal Diseases studies recruiting now, 48 (47%) set no upper age limit and 42 (41%) stop at 75 or younger; 5 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
160 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 22 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 48 is close to the median of 45 across 559 interventional studies indexed under Periodontal Diseases.
Median enrollment 60 across the 69 interventional studies, 88 across the 91 observational. Of the 123 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 160 have an industry lead sponsor. The 10 most frequent:
Ordu University is the lead sponsor of 34 studies on the registry; 12 are open to participants now.
Ordu University has 2 studies filed under Periodontal Diseases — fewer than ten, so there is no comparison to draw.
10 of the studies in Periodontal Diseases with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07312045Ömer Faruk OkumuşHALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy | 2026-11-25 |
| NCT07887204Istanbul UniversityAntibiotic Resistance Genes in Periodontitis | 2026-12 |
| NCT07146776Saglik Bilimleri UniversitesiTreatment of Intrabony Defects With Injectable Platelet-Rich Fibrin and Xenogenic Grafts | 2026-12-01 |
| NCT07802249Ravan MammadovPeriodontal Health in Adults Treated With Fixed Orthodontic Appliances or Clear Aligners | 2026-12-25 |
| NCT07944911Ordu UniversityChanges in Taurine Levels After Non-Surgical Periodontal Treatment and Their Association With Inflammatory and Apoptosis Marker | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 160 studies in Periodontal Diseases with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to measure taurine, IL-1β, IL-10, myeloperoxidase, and caspase-3 levels in gingival crevicular fluid (GCF) and saliva of individuals with periodontal disease, to compare these parameters with those of periodontally healthy individuals, and to evaluate the associations between taurine levels and inflammatory and apoptotic markers. Furthermore, the study aims to compare changes in these parameters before and after non-surgical periodontal treatment in individuals with periodontal disease.
Taurine, a sulfur-containing amino acid, plays an important role in antioxidant and anti-inflammatory processes. Interleukin-1β (IL-1β), a pro-inflammatory cytokine, is a key mediator of periodontal inflammation and tissue destruction, whereas interleukin-10 (IL-10) is an anti-inflammatory cytokine that helps regulate inflammatory responses. Myeloperoxidase (MPO), a marker of neutrophil activation, contributes to the inflammatory response through the production of reactive oxidants, whereas caspase-3 is a key executioner enzyme involved in apoptosis and programmed cell death. This study aimed to investigate taurine, IL-1β, IL-10, MPO, and caspase-3 levels in saliva and gingival crevicular fluid (GCF) of individuals with periodontitis, gingivitis, and periodontal health, and to evaluate changes in these biomarkers following non-surgical periodontal treatment.
Materials and Methods: A total of 48 systemically healthy individuals were included in the study and divided into three groups: individuals with Stage III Grade B periodontitis, individuals with gingivitis, and periodontally healthy individuals. Clinical periodontal parameters, including the Silness and Löe Plaque Index (PI), Löe and Silness Gingival Index (GI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP), were recorded. Routine radiographic examinations were also performed to assess alveolar bone levels.
Gingival crevicular fluid (GCF) and unstimulated saliva samples were collected from all three groups at baseline to determine taurine, IL-1β, IL-10, caspase-3, and MPO levels. In the gingivitis and periodontitis groups, clinical examinations and sample collection were repeated at the sixth week following non-surgical periodontal treatment. The levels of these biomarkers were quantified using enzyme-linked immunosorbent assay (ELISA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Systemically healthy and patients with periodontally healthy
Other: Periodontally healthy group
systemically healthy and patients with Stage III Grade B periodontitis
Other: Non-surgical periodontal treatment
Systemically healthy and patients with Gingivitis
Other: Non-surgical periodontal treatment
Non-surgical periodontal treatment consisting of supragingival scaling and subgingival instrumentation using periodontal scalers and curettes in individuals with Stage III Grade B periodontitis.
Periodontally healthy individuals who did not receive periodontal treatment. GCF and unstimulated saliva samples were collected at baseline.
Professional supragingival scaling and plaque removal performed in individuals with gingivitis.
Plaque Index
to assess plaque accumulation
Time frame: Baseline
Plaque Index
to assess plaque accumulation
Time frame: 6 weeks post-treatment
Gingival Index
for evaluating gingival inflammation
Time frame: Baseline
Gingival Index
for evaluating gingival inflammation
Time frame: 6 weeks post-treatment
Probing pocket depth
for measuring disease severity
Time frame: Baseline
Probing pocket depth
for measuring disease severity
Time frame: 6 weeks post-treatment
clinical attachment level
Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.
Time frame: Baseline
clinical attachment level
Clinical attachment level (CAL) is calculated by adding or subtracting probing depth (PD) and gingival recession (GR). The formula is CAL = PD + GR. CAL is measured in millimeters.
Time frame: 6 weeks post-treatment
Bleeding on Probing
to assess disease activity
Time frame: Baseline
Bleeding on Probing
to assess disease activity
Time frame: 6 weeks post-treatment
IL-1β
IL-1β levels in gingival crevicular fluid (GCF) and saliva
Time frame: Baseline
IL-1β
IL-1β levels in gingival crevicular fluid (GCF) and saliva
Time frame: 6 weeks post-treatment
Taurine
Taurine levels in gingival crevicular fluid (GCF) and saliva
Time frame: Baseline
Taurine
Taurine levels in gingival crevicular fluid (GCF) and saliva
Time frame: 6 weeks post-treatment
Caspase-3
Caspase-3 levels in gingival crevicular fluid (GCF) and saliva
Time frame: Baseline
Caspase-3
Caspase-3 levels in gingival crevicular fluid (GCF) and saliva
Time frame: 6 weeks post-treatment
Myeloperoxidase
Myeloperoxidase levels in gingival crevicular fluid (GCF) and saliva
Time frame: Baseline
Myeloperoxidase
Myeloperoxidase levels in gingival crevicular fluid (GCF) and saliva
Time frame: 6 weeks post-treatment
IL-10
IL-10 levels in gingival crevicular fluid (GCF) and saliva
Time frame: Baseline
IL-10
IL-10 levels in gingival crevicular fluid (GCF) and saliva
Time frame: 6 weeks post-treatment
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Mar 2027, 4 months after the start.
Of 314 non-industry interventional studies with no phase under Periodontal Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 4 months is below that.
Counting every sponsor, half of 333 studies reached it within 13 months; a quarter within 8 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ordu University